Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of CNP520 in Healthy Elderly Subjects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Antwerpen, Belgium, 2060
- Novartis Investigative Site
-
-
-
-
-
Berlin, Germany, 14050
- Novartis Investigative Site
-
-
-
-
-
Leiden, Netherlands, 2333 CL
- Novartis Investigative Site
-
-
GZ
-
Groningen, GZ, Netherlands, 9713
- Novartis Investigative Site
-
-
-
-
-
Harrow, United Kingdom, HA1 3UJ
- Novartis Investigative Site
-
Mid Glamorgan, United Kingdom, CF484DR
- Novartis Investigative Site
-
-
Northern Ireland
-
Belfast, Northern Ireland, United Kingdom, BT9 6AD
- Novartis Investigative Site
-
-
-
-
California
-
Glendale, California, United States, 91206
- Novartis Investigative Site
-
Long Beach, California, United States, 90806
- Novartis Investigative Site
-
-
Florida
-
Miami, Florida, United States, 33126
- Novartis Investigative Site
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68502
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
- Healthy status
- Body weight: ≥45kg
- BMI: 18-34 kg/m2
Key Exclusion Criteria:
- History or presence of any clinically significant disease of any major system organ class.
- Heavy smoker status
- History /presence of clinically significant neurological or psychiatric disorders
- Any medical condition that might lead to or is associated with any cognitive deficit
- History or presence of severely impaired renal function
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
Matching placebo to CNP520 was taken once daily (qd) orally for 13 weeks.
|
Matching placebo to CNP520 was supplied in capsules.
|
|
Experimental: CNP520 2 mg
CNP520 2 mg was taken qd orally for 13 weeks.
|
Other Names:
|
|
Experimental: CNP520 10 mg
CNP520 10 mg was taken qd orally for 13 weeks.
|
Other Names:
|
|
Experimental: CNP520 35 mg
CNP520 35 mg was taken qd orally for 13 weeks.
|
Other Names:
|
|
Experimental: CNP520 85 mg
CNP520 85 mg was taken qd orally for 13 weeks.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Subjects With Non-serious and Serious Adverse Events (AEs) and Deaths
Time Frame: 13 weeks
|
Safety monitoring was conducted throughout the study.
|
13 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline of Amyloid Beta (Aβ) 1-38 , Aβ 1-40 and Aβ 1-42 Cerebrospinal Fluid (CSF) Concentrations
Time Frame: Day 92
|
CSF samples were collected by lumbar puncture for assessment.
|
Day 92
|
|
Summary of Plasma PK Parameter: Cmax
Time Frame: Days 1, 91
|
Cmax = the observed maximum plasma concentration following drug administration.
Blood samples were collected to assess Cmax.
The PK analysis set was used for the analysis.
|
Days 1, 91
|
|
Summary of Plasma PK Parameter: AUCtau
Time Frame: Days 1 and 91
|
AUCtau = the area under the plasma concentration-time curve from zero to the end of the dosing interval tau.
Blood samples were collected to assess AUCtau.
|
Days 1 and 91
|
|
Summary of Plasma PK Parameter: Tmax
Time Frame: Days 1 and 91
|
Tmax = the time to reach the maximum concentration after drug administration.
Blood samples were collected to assess Tmax.
|
Days 1 and 91
|
|
Summary of Plasma PK Parameter: Tlag
Time Frame: Days 1 and 91
|
Tlag = time delay between drug administration and first observed concentration above the lower limit of quantification (LOQ) in plasma .
Blood samples were collected to assess Tlag.
|
Days 1 and 91
|
|
Summary of Plasma PK Parameter: T1/2
Time Frame: Day 91
|
T1/2 = the terminal elimination half-life.
Blood samples were collected to assess T/12.
|
Day 91
|
|
Summary of PK Parameter: CLss/F
Time Frame: Day 91
|
CLss/F = the apparent systemic clearance from plasma observed during a dosing interval at steady state following extravascular administration.
Blood samples were collected to assess CLss/F.
|
Day 91
|
|
Summary of Plasma PK Parameter: Racc
Time Frame: Day 91
|
Racc = the accumulation ratio .
Blood samples were collected to assess Racc.
|
Day 91
|
|
Summary of CSF PK Concentrations
Time Frame: Days 1, 14, 28, 42, 56, 70 and 91
|
CSF samples were collected by lumbar puncture for assessment.
|
Days 1, 14, 28, 42, 56, 70 and 91
|
|
Area-under-plasma Concentration Time Curve up to Infinity (AUCinf)
Time Frame: Day 91
|
CNP520 concentrations in plasma
|
Day 91
|
|
Apparent Volume of Distribution (Vz/F)
Time Frame: Day 91
|
Day 91
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CCNP520X2102
- 2013-005576-18 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.